A Phase 2 interventional study of CaCP29 and Placebo in Severe Sepsis and Septic Shock, sponsored by InflaRx GmbH. Completed at 11 sites in Germany. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-04-25.
Sponsored by InflaRx GmbH · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 56 studies in Shock, Septic with a site in Germany — 7 open to participants now, 7 under way, none of them phase 3. Shock, Septic · Germany.
Among the 56 studies in Shock, Septic with a site in Germany, this one is the 20th largest by enrollment of the 29 interventional ones that give a count, is one of 2 that started in 2014, is one of 5 in phase 2, and was the 21st registered.
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
Browse Shock, Septic studies →7 of the 56 studies in Shock, Septic with a site in Germany are open now. Recruiting first, the newest first:
Artcline GmbH · Sites in Germany
Ages 18+
Hannover Medical School · Sites in Germany, Austria, Switzerland
Ages 18–80
Charite University, Berlin, Germany · Sites in Germany
Ages 18+
CytoSorbents, Inc · Sites in Germany, Austria, Italy and 3 more countries
Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe Seps · Sites in Germany
Ages 18–99
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 137 Shock, Septic studies recruiting now, 102 (74%) set no upper age limit and 19 (14%) stop at 75 or younger; 12 take children under 18; 13 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
56 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 6 · Phase 3 8
First in 2002; this study’s year is marked. 2 started in 2014.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 72 is close to the median of 79 across 636 interventional studies indexed under Shock, Septic.
Median enrollment 277 across the 29 interventional studies, 275 across the 26 observational. Of the 33 that completed or were terminated, 4 (12%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 56 have an industry lead sponsor. The 10 most frequent:
InflaRx GmbH is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
InflaRx GmbH has 1 study filed under Shock, Septic — fewer than ten, so there is no comparison to draw.
4 of the studies in Shock, Septic with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05688774Pneumonia Research Network on Genetic Resistance and Susceptibility for the Evolution of Severe SepsStudy of Progression of Community Acquired Pneumonia in the Hospital in Patients With More Severe Preexisting Diseases and Immunosuppression | 2027-02-28 |
| NCT07388628Artcline GmbHARTICE® Real Data Collection & Observational Trial, Phase 4 Study | 2027-09 |
| NCT03334006RWTH Aachen UniversityProspective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis | 2027-09 |
| NCT07817043University Medicine GreifswaldMicrobiology Operations & Time Optimization in Sepsis | 2027-10-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 56 studies in Shock, Septic with a site in Germany, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The trial enrolls patients with early severe sepsis or septic shock displaying at least one newly developed organ dysfunction and showing clinical evidence of pulmonary or abdominal infection. The primary goal of the trial is to assess the pharmacokinetics and pharmacodynamics of the new monoclonal antibody CaCP29 and to characterize safety and tolerability as well as evaluate parameters of efficacy.
1,079 studies on the registry are indexed under Shock, Septic; 233 are open to participants now.
This study's enrollment of 72 is close to the median of 79 across 636 interventional studies indexed under Shock, Septic.
Browse Shock, Septic studies →InflaRx GmbH is the lead sponsor of 12 studies on the registry; none are open to participants now.
Of its 8 completed or terminated interventional studies of FDA-regulated products, 6 (75%) have results posted.
Compared within Shock, Septic, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Sepsis. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Key Inclusion Criteria at screening:
At least one of the following acute organ dysfunctions due to sepsis. Each organ dysfunction must have occurred within 12 hours prior to screening, cannot mainly be explained by other disease processes than sepsis and is judged by the investigator as being caused or directly related to an abdominal or pulmonary infectious focus:
Key Exclusion Criteria at screening:
Patients receiving the following concomitant medication within 14 days prior to screening:
General criteria:
Inclusion Criteria at randomisation:
Exclusion Criteria at randomisation:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
dose escalating i.v. administration of CaCP29 (verum)
Biological: CaCP29
dose escalation mimicing i.v. placebo treatment:
Biological: Placebo
Also known as: IFX-1
Plasma Concentration of CaCP29
Pharmacokinetic measures include * Plasma concentration over time * Maximum observed concentration per infusion * Concentration measured immediately before next dosing * Area under the curve of plasma concentration per infusion * Mean concentration per infusion * Terminal phase half-life
Time frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
Assess the pharmacodynamic (PD) effects of CaCP29 on the change from baseline in plasma concentrations of C5a
Time frame: 0h, 2h, 6h, 12h, 14h (only cohort 1), 24h, 26h (only cohort 2 and 3), 48h, 72h, 74h (only cohort 3), days 5, 8, 13, 28
Safety variables will be summarized using descriptive statistics based on adverse event collection
Time frame: 28 days
Anti-drug antibodies (ADA)
The development of ADA will be described by: * Number of patients with detection of anti-drug antibody (ADA) * Number of patients with detection of ADA at each time point measured
Time frame: 28 days or hospital discharge
All-cause mortality rate
Time frame: 28 days
Morbidity
* Mean SOFA until Day 10 * Modified mean SOFA until day 10 (calculated by omitting the Central Nervous System sub-score and calculating the renal subscore without taking urine output into consideration) * Mean SOFA Sub-scores until Day 10 * Days on ICU until Day 28 * Number of patients ventilated until Day 14 * Ventilator-free days until Day 14 * Numbers of patients with renal replacement therapy (RRT) until Day 14 * RRT-free days until Day 14 * Numbers of patients with administration of vasopressor until Day 14 * Vasopressor-free days until Day 14 * Days without antimicrobial therapy (AMT) until Day 14
Time frame: daily
Fluid balance
* Mean daily total fluid intake until Day 28 (maximal until ICU discharge) * Mean daily total fluid output until Day 28 (maximal until ICU discharge) * Mean daily fluid balance until Day 28 (maximal until ICU discharge)
Time frame: 28 days or ICU discharge
Change in routine laboratory parameters as compared to baseline
Time frame: Days 1, 2, 3, 4, 5, 8, 13, 28
Change in ECG as compared to baseline
Time frame: Days 2, 4, 8, 28
Change in vital signs as compared to baseline
Time frame: Days 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, Day 28
The record gives a start of Apr 2014, a primary completion of Dec 2015 and a completion of Dec 2015. It does not say whether these dates are actual or estimated.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vilobelimab
InflaRx GmbH